A double-blind evaluation of transfer factor therapy of HBsAg-positive chronic aggressive hepatitis

Preliminary report of efficacy

Stanford T. Shulman*, Jack H. Hutto, Elia M. Ayoub, Steven A. Howlett, Barry Scott, James E. McGuigan

*Corresponding author for this work

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

A controlled, prospective, double-blind trial of transfer factor in chronic aggressive hepatitis was carried out. This report presents the results obtained from study of the nine HBsAg-positive subjects who were included in the trial. Transfer factor was prepared from adults who had recovered from acute hepatitis B or from acute non-B viral hepatitis and was administered to five HBsAg-positive subjects. Four HBsAg-seropositive subjects received placebo. Percutaneous liver biopsy was performed at the beginning and at the conclusion of the 10-week study period; biochemical and clinical parameters were monitored throughout. Cell-mediated immunity was assessed at the beginning and at the end of the study period. Four of five transfer factor recipients showed moderate or marked improvement in hepatic histology, clinical status, and serum transaminase levels, while none of four placebo recipients demonstrated improvement. The difference in response between the two groups was significant (P = 0.048). No consistent changes in in vivo or in vitro correlates of cell-mediated immunity were demonstrated. No adverse effects were noted among transfer factor recipients. These data suggest that transfer factor may be of benefit in chronic aggressive hepatitis associated with HBsAg. Additional studies appear to be indicated to delineate the mode of action of transfer factor as well as the role that such immunotherapy should play in the management of patients with this disorder.

Original languageEnglish (US)
Pages (from-to)352-361
Number of pages10
JournalCellular Immunology
Volume43
Issue number2
DOIs
StatePublished - Mar 15 1979

Fingerprint

Transfer Factor
Chronic Hepatitis
Hepatitis B Surface Antigens
Cellular Immunity
Therapeutics
Placebos
Liver
Transaminases
Hepatitis B
Immunotherapy
Hepatitis
Histology
Biopsy
Serum

ASJC Scopus subject areas

  • Immunology

Cite this

Shulman, Stanford T. ; Hutto, Jack H. ; Ayoub, Elia M. ; Howlett, Steven A. ; Scott, Barry ; McGuigan, James E. / A double-blind evaluation of transfer factor therapy of HBsAg-positive chronic aggressive hepatitis : Preliminary report of efficacy. In: Cellular Immunology. 1979 ; Vol. 43, No. 2. pp. 352-361.
@article{1f9f4ab1307b456c997e4a269901de9f,
title = "A double-blind evaluation of transfer factor therapy of HBsAg-positive chronic aggressive hepatitis: Preliminary report of efficacy",
abstract = "A controlled, prospective, double-blind trial of transfer factor in chronic aggressive hepatitis was carried out. This report presents the results obtained from study of the nine HBsAg-positive subjects who were included in the trial. Transfer factor was prepared from adults who had recovered from acute hepatitis B or from acute non-B viral hepatitis and was administered to five HBsAg-positive subjects. Four HBsAg-seropositive subjects received placebo. Percutaneous liver biopsy was performed at the beginning and at the conclusion of the 10-week study period; biochemical and clinical parameters were monitored throughout. Cell-mediated immunity was assessed at the beginning and at the end of the study period. Four of five transfer factor recipients showed moderate or marked improvement in hepatic histology, clinical status, and serum transaminase levels, while none of four placebo recipients demonstrated improvement. The difference in response between the two groups was significant (P = 0.048). No consistent changes in in vivo or in vitro correlates of cell-mediated immunity were demonstrated. No adverse effects were noted among transfer factor recipients. These data suggest that transfer factor may be of benefit in chronic aggressive hepatitis associated with HBsAg. Additional studies appear to be indicated to delineate the mode of action of transfer factor as well as the role that such immunotherapy should play in the management of patients with this disorder.",
author = "Shulman, {Stanford T.} and Hutto, {Jack H.} and Ayoub, {Elia M.} and Howlett, {Steven A.} and Barry Scott and McGuigan, {James E.}",
year = "1979",
month = "3",
day = "15",
doi = "10.1016/0008-8749(79)90179-5",
language = "English (US)",
volume = "43",
pages = "352--361",
journal = "Cellular Immunology",
issn = "0008-8749",
publisher = "Academic Press Inc.",
number = "2",

}

A double-blind evaluation of transfer factor therapy of HBsAg-positive chronic aggressive hepatitis : Preliminary report of efficacy. / Shulman, Stanford T.; Hutto, Jack H.; Ayoub, Elia M.; Howlett, Steven A.; Scott, Barry; McGuigan, James E.

In: Cellular Immunology, Vol. 43, No. 2, 15.03.1979, p. 352-361.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A double-blind evaluation of transfer factor therapy of HBsAg-positive chronic aggressive hepatitis

T2 - Preliminary report of efficacy

AU - Shulman, Stanford T.

AU - Hutto, Jack H.

AU - Ayoub, Elia M.

AU - Howlett, Steven A.

AU - Scott, Barry

AU - McGuigan, James E.

PY - 1979/3/15

Y1 - 1979/3/15

N2 - A controlled, prospective, double-blind trial of transfer factor in chronic aggressive hepatitis was carried out. This report presents the results obtained from study of the nine HBsAg-positive subjects who were included in the trial. Transfer factor was prepared from adults who had recovered from acute hepatitis B or from acute non-B viral hepatitis and was administered to five HBsAg-positive subjects. Four HBsAg-seropositive subjects received placebo. Percutaneous liver biopsy was performed at the beginning and at the conclusion of the 10-week study period; biochemical and clinical parameters were monitored throughout. Cell-mediated immunity was assessed at the beginning and at the end of the study period. Four of five transfer factor recipients showed moderate or marked improvement in hepatic histology, clinical status, and serum transaminase levels, while none of four placebo recipients demonstrated improvement. The difference in response between the two groups was significant (P = 0.048). No consistent changes in in vivo or in vitro correlates of cell-mediated immunity were demonstrated. No adverse effects were noted among transfer factor recipients. These data suggest that transfer factor may be of benefit in chronic aggressive hepatitis associated with HBsAg. Additional studies appear to be indicated to delineate the mode of action of transfer factor as well as the role that such immunotherapy should play in the management of patients with this disorder.

AB - A controlled, prospective, double-blind trial of transfer factor in chronic aggressive hepatitis was carried out. This report presents the results obtained from study of the nine HBsAg-positive subjects who were included in the trial. Transfer factor was prepared from adults who had recovered from acute hepatitis B or from acute non-B viral hepatitis and was administered to five HBsAg-positive subjects. Four HBsAg-seropositive subjects received placebo. Percutaneous liver biopsy was performed at the beginning and at the conclusion of the 10-week study period; biochemical and clinical parameters were monitored throughout. Cell-mediated immunity was assessed at the beginning and at the end of the study period. Four of five transfer factor recipients showed moderate or marked improvement in hepatic histology, clinical status, and serum transaminase levels, while none of four placebo recipients demonstrated improvement. The difference in response between the two groups was significant (P = 0.048). No consistent changes in in vivo or in vitro correlates of cell-mediated immunity were demonstrated. No adverse effects were noted among transfer factor recipients. These data suggest that transfer factor may be of benefit in chronic aggressive hepatitis associated with HBsAg. Additional studies appear to be indicated to delineate the mode of action of transfer factor as well as the role that such immunotherapy should play in the management of patients with this disorder.

UR - http://www.scopus.com/inward/record.url?scp=0018741619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018741619&partnerID=8YFLogxK

U2 - 10.1016/0008-8749(79)90179-5

DO - 10.1016/0008-8749(79)90179-5

M3 - Article

VL - 43

SP - 352

EP - 361

JO - Cellular Immunology

JF - Cellular Immunology

SN - 0008-8749

IS - 2

ER -